Lipid-lowering therapy in people with type 2 diabetes

Current Opinion in Lipidology

Volumn 13, Issue 6, 2002, Pages 617-623

  Colagiuri, Stephen ^a   Best, James ^b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cardiovascular disease; Diabetes; Lipid lowering therapy

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ASCORBIC ACID; BETA CAROTENE; BEZAFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; STATIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; DRUG EFFICACY; DYSLIPIDEMIA; HUMAN; INSULIN RESISTANCE; LIFESTYLE; LIPID BLOOD LEVEL; LIPID METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOMES RESEARCH; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE;

ANTILIPEMIC AGENTS; DIABETES MELLITUS, TYPE 2; FOLLOW-UP STUDIES; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIFE STYLE; LIPIDS; RISK FACTORS; TREATMENT OUTCOME;

EID: 0036914057     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200212000-00004     Document Type: Review

References (46)

1. Best J, Colagiuri S, Malouf N, et al. Evidence Based Guidelines for Type 2 Diabetes: Management of Lipid Abnormalities. 2002 [last accessed 25 September 2002]. www.diabetesaustralia.com.au. Australian guidelines specifically addressing a broad range of issues relating to lipids and their management in people with type 2 diabetes.
2. Cowie CC, Howard BV, Harris MI. Serum lipoproteins in African Americans and whites with non-insulin-dependent diabetes in the US population. Circulation 1994; 90:1185-1193.
3. Ronnemaa T, Laakso M, Kallio V, et al. Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients. Am J Epidemiol 1989; 130:632-645.
4. Siegel RD, Cupples A, Schaefer EJ, Wilson PWF, Lipoproteins, apolipoproteins, and low-density lipoprotein size among diabetics in the Framingham Offspring Study. Metabolism 1996; 45:1267-1272.
5. Brunzell JD, Hokanson JE. Dyslipidemia of central obesity and insulin resistance. Diabetes Care 1999; 22 (Suppl 3):C10-C13.
6. Stamler J, Vaccaro O, Neaton JD, Wentworth D, For the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16:434-444.
7. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151:1141-1147.
8. Turner RC, Millns H, Neil HAW, et al., for the United Kingdom Prospective Diabetes Study Group. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS:23). BMJ 1998; 316:823-828.
9. Brown SA, Winter M, Upchurch S, et al. Promoting weight loss in type II diabetes. Diabetes Care 1996; 19:613-624.
10. Garg A. High-monounsaturated-fat diets for patients with diabetes mellitus: A meta-analysis. Am J Clin Nutr 1998; 67 (Suppl 1):577-582.
11. Stern MP, Mitchell BD, Haffner SM, Hazuda HP. Does glycaemic control of type II diabetes suffice to control diabetic dyslipidemia? A community perspective. Diabetes Care 1992; 15:638-644.
12. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088-2093.
13. Elkeles RS, Diamond JR, Poulter C, et al., the SENDCAP Study Group. Cardiovascular outcomes in type 2 diabetes. A double-blind placebo-controlled study of bezafibrate: The St Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) Study. Diabetes Care 1998; 21:641-648.
14. DAIS Investigators. Effects on fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905-910.
15. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101:207-213.
16. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidaemia in non-insulin dependent diabetes mellitus. JAMA 1990; 264:723-726.
17. Garg A, Grundy SM. Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. Ann Intern Med 1994; 121:416-422.
18. Friedberg CE, Janssen MJ, Heine RJ, Grobbee DE. Fish oil and glycemic control in diabetes. A meta-analysis. Diabetes Care 1998; 21:494-500.
19. Montori VM, Farmer A, Wollan PC, Dinneen SF. Fish oil supplementation in type 2 diabetes. Diabetes Care 2000; 23:1407-1415.
20. Athyros VG, Papageorgiou AA, Athyrou VV, et al. Atorvastatin and micronised fenofibrtae alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002; 25:1198-1202. This study examines the effects of combination therapy in people with diabetes, and reports improved lipid levels without an increase in side-effects.
21. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997; 20:614-620.
22. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
23. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analysis in the Cholesterol and Recurrent Events (CARE) Trial. Circulation 1998; 98:2513-2519.
24. The LIPID Study Group. Long-term effectivenesss and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 2002; 359:1379-1387. Reports longer-term follow-up data on the LIPID study showing that the findings hold for up to 8 years.
25. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project. Circulation 2000; 102:1893-1900.
26. Downs JR, Clearfield M, Weis S, et al., for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279:1615-1622.
27. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Saftey of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237-1245.
28. Haffner SM, Alexander CM, Cook TJ, et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med 1999; 159:2661-2667.
29. LIPID Group. Long-term intervention with pravastatin in ischaemic disease. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
30. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuls: A randomised placebo-controlled trial. Lancet 2002; 360:7-22. The largest study to date of statin therapy in high-risk people with a broad range of cholesterol levels at entry. This study included a large number of people with diabetes and provides information on both primary and secondary CHD prevention.
31. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of anti-oxidant vitamin supplementation in 20,536 high-risk individuls: A randomised placebo-controlled trial. Lancet 2002; 360:23-33 Reports the lack of effect on CHD outcomes of anti-oxidant vitamin supplementation in high-risk people with a broad range of cholesterol levels at entry.
32. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1306.
33. Bloomfield-Rubins H, Robins SJ, Collins D, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999; 341:410-418.
34. BIP Group. Bezafibrate Infarction Prevention. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. The Benzafibrate Infarction Prevention (BIP) Study. Circulation 2000; 102:21-27.
35. Koskinen P, Manttari M, Manninen V, et al. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15:820-825.
36. Huang ES, Meigs JB, Singer DE. The effect of interventions to prevent cardiiovascular disease in patients with type 2 diabetes mellitus. Am J Med 2001; 111:633-642. A meta-analysis of interventions to lower cholesterol, blood pressure and blood glucose in people with type 2 diabetes demonstrating improved CVD outcomes with lipid and blood pressure lowering.
37. Grundy SM. Statin trials and goals of cholesterol-lowering therapy. Circulation 1998; 97:1436-1439.
38. West of Scotland Coronary Prevention Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440-1445.
39. Pedersen TR, Olsson AG, Faergeman O, et al., for The Scandinavian Simvastatin Survival Study Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998; 97:1453-1460.
40. Sachs F, Tonkin AM, Craven T, et al. Coronary heart disease in patients with low LD L-cholesterol: Benefits of pravastatin in diabetics and enhanced role for HDL-cholesterol and trigiycerides as risk factors. Circulation 2002; 105:1424-1428. Pooled analysis of the CARE and LIPID studies showing improved CHD outcomes with statin therapy in people with diabetes and LDL cholesterol less than 3.2 mmol/I.
41. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2002; 25 (Suppl 1):S74-S77. Consensus guidelines on the various aspects of lipids and diabetes.
42. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-243.
43. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: Cross sectional and cohort studies. BMJ 2002; 324:939-942. A large cross-sectional and cohort study comparing death and other outcomes in people with diabetes and people without diabetes who have had a previous myocardial infarction. This study does not support their equivalent risk.
44. McIntosh A, Hutchinson A, Feder G, Home P. Clinical Guidelines for Type 2 Diabetes: Lipid Management. London: Royal College of General Practitioners; 2001. UK guidelines specifically addressing a broad range of issues relating to lipids and their management in people with type 2 diabetes.
45. Yeo WW, Yeo KW. Predicting CHD in patients with diabetes mellitus. Diabet Med 2001; 18:341-344.
46. Stevens R, Kothari V, Adler Al, et al., UKPDS 56. The UKPDS Risk Engine: A model for the risk of coronary heart disease in type 2 diabetes. Clin Sci 2001; 101:671-679. An absolute-risk calculator developed specifically for people with diabetes based on the results of the UKPDS.